CPT 91323 mRNA COVID-19 Vaccine Reimbursement

CPT code 91323 designates an mRNA-based COVID-19 vaccine product supplied for intramuscular administration at a dosage of 10 micrograms per 0.2 mL. This code captures the vaccine product itself and is integral to national vaccination efforts, facilitating standardized reporting, coverage determinations, and public health tracking. Its use matters for immunization programs, payer coverage policies, and provider billing workflows across ambulatory care settings.

Key payers included in discussions of CPT code 91323 are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national view of the code’s clinical context, common settings where the vaccine is administered, and the payer landscape relevant to coverage and claims processing. The publication provides benchmarks for utilization and reimbursement trends where available, notes on billing considerations, and summaries of recent policy updates affecting vaccine product coding and payment. Clinical context covers the mRNA platform and intramuscular route of administration, including dose specification. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 91323 represents a COVID-19 vaccine product using mRNA technology, administered intramuscularly. The listed dosage is 10 micrograms per 0.2 mL, indicating a specific vaccine formulation and measured volume for a single dose.

Service Type: Vaccination — intramuscular administration of an mRNA COVID-19 vaccine product

Typical Site of Service: Outpatient clinic, pharmacy, public health clinic, or other ambulatory vaccination settings where intramuscular immunizations are provided

Clinical Context

A typical patient is an adult or adolescent who presents to an outpatient vaccination clinic, primary care office, occupational health clinic, pharmacy clinic, or community vaccination site for administration of a COVID-19 mRNA booster or primary series dose. The vaccine represented by 91323 is a 10 microgram (0.2 mL) intramuscular mRNA formulation given in the deltoid muscle. Workflow steps include: pre-vaccination screening for contraindications and recent COVID-19 infection, verification of immunization consent and history, documentation of vaccine lot number and expiration, preparation of the 0.2 mL dose per manufacturer instructions, administration via intramuscular injection, monitoring the patient for immediate adverse reactions for at least 15 minutes (longer if history of anaphylaxis), post-vaccination counseling including expected local and systemic reactions, and entry of the immunization into the patient’s electronic medical record and any required immunization registry. Typical sites of service are outpatient clinics, pharmacies, community vaccination sites, and primary care or pediatric offices. Common patient scenarios include routine booster dose administration, completion of a primary series for eligible patients, and administration in medically high-risk individuals per current public health guidance.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no special modifier applies to the vaccine administration claim

Taxonomy Code	Specialty	Notes
`207Q00000X`	Family Medicine	Primary care clinicians who commonly administer vaccines in outpatient settings
`207R00000X`	Internal Medicine	Adult primary care providers administering COVID-19 vaccines
`363A00000X`	Public Health & General Preventive Medicine	Providers working in public health clinics and mass vaccination sites
`363L00000X`	Pharmacy	Pharmacists and pharmacy-based immunizers who routinely provide vaccine administration
`367500000X`	Pediatrics	Pediatricians providing vaccination for eligible adolescent patients

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z23`	Encounter for immunization	Primary billing diagnosis to report routine vaccination encounters, appropriate for administration of `91323`
`U07.1`	COVID-19, virus identified	May be used when documenting recent or current COVID-19 infection; typically relevant for screening and timing of vaccination
`Z28.3`	Encounter for immunization against single specific disease	Used when documenting encounter specifically for COVID-19 immunization in some payer systems
`Z71.89`	Other specified counseling	Used when significant vaccine counseling beyond routine is provided and documented
`T78.2XXA`	Anaphylactic shock, unspecified, initial encounter	Relevant for documentation if anaphylaxis occurs as an adverse reaction to vaccination (use appropriate extension and encounter coding)

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`90460`	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first vaccine/toxoid component	Used when counseling and administration for a pediatric vaccine occur; documents vaccine counseling plus administration when applicable to age criteria
`90461`	Immunization administration through 18 years of age; each additional vaccine/toxoid component	Used to report additional vaccine components administered during the same visit for pediatric patients
`90471`	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid)	Commonly reported for single vaccine administration when `91323` is billed as the vaccine product (administration code paired as required by payer rules)
`90472`	Each additional vaccine (single or combination vaccine/toxoid)	Reported for additional vaccines administered at the same encounter
`99072`	Additional supplies, materials, and clinical staff time over and above those usually included with the primary service, when requested by patient, parent or guardian (e.g., vaccines requiring special handling)	Used when extra supplies or cold-chain handling beyond routine are required for vaccine storage or administration
`G0008`	Administration of influenza vaccine (Medicare only)	Included here as a related administration code for payer-specific guidance; not used for COVID-19 vaccine billing but shown for workflow comparison

OpenPayer

Summary & Overview

CPT 91323: mRNA COVID-19 Vaccine, 10 mcg/0.2 mL Intramuscular